279 related articles for article (PubMed ID: 37470280)
1. Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities.
Goodman RS; Jung S; Balko JM; Johnson DB
Immunol Rev; 2023 Sep; 318(1):157-166. PubMed ID: 37470280
[TBL] [Abstract][Full Text] [Related]
2. Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.
Arora S; Velichinskii R; Lesh RW; Ali U; Kubiak M; Bansal P; Borghaei H; Edelman MJ; Boumber Y
Adv Ther; 2019 Oct; 36(10):2638-2678. PubMed ID: 31410780
[TBL] [Abstract][Full Text] [Related]
3. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.
Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
5. Immune mechanisms of toxicity from checkpoint inhibitors.
Wang SJ; Dougan SK; Dougan M
Trends Cancer; 2023 Jul; 9(7):543-553. PubMed ID: 37117135
[TBL] [Abstract][Full Text] [Related]
6. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.
Xu Y; Fu Y; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():2023. PubMed ID: 33123120
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
8. Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors.
Salewski I; Kuntoff S; Kuemmel A; Feldtmann R; Felix SB; Henze L; Junghanss C; Maletzki C
Cancer Immunol Immunother; 2021 Dec; 70(12):3405-3419. PubMed ID: 33870463
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
11. The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer.
Xu Y; Zuo F; Wang H; Jing J; He X
Front Immunol; 2022; 13():1045957. PubMed ID: 36389711
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
13. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
[TBL] [Abstract][Full Text] [Related]
14. Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance.
Bielska AA; Chatila WK; Walch H; Schultz N; Stadler ZK; Shia J; Reidy-Lagunes D; Yaeger R
J Natl Compr Canc Netw; 2021 Feb; 19(2):130-133. PubMed ID: 33545685
[TBL] [Abstract][Full Text] [Related]
15. Could the immune checkpoint inhibitor against colorectal cancer in constitutional mismatch repair deficiency syndrome prevent new cancer formation?
Tanimura K; Yamasaki K; Matsubara K; Noguchi M; Kikuchi N; Nitani C; Okada K; Fujisaki H; Okuno T; Inoue T; Nebiki H; Akagi K; Tomita N; Hara J
Pediatr Blood Cancer; 2022 Jan; 69(1):e29312. PubMed ID: 34453473
[No Abstract] [Full Text] [Related]
16. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.
Bartoletti M; Giorda G; Viel A; Fornasarig M; Zdjelar A; Segatto E; Sorio R; Corsetti S; Scalone S; Nicoloso MS; Pivetta T; Lucia E; Clemente N; Palazzari E; Canzonieri V; Puglisi F
Curr Oncol; 2022 Jul; 29(8):5209-5212. PubMed ID: 35892982
[TBL] [Abstract][Full Text] [Related]
17. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
18. Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition.
Zheng G; Lu Y; Yang Z; Chen H; Liang Q; Zhu Q; Li Y; Xiao X; He Z; Zhu Y; Li B; Huang L; Dong N; Hu S; Pan Y; Zhang C; Zhu C
Front Immunol; 2023; 14():1142862. PubMed ID: 37187745
[TBL] [Abstract][Full Text] [Related]
19. Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade.
Graham LS; Pritchard CC; Schweizer MT
Clin Cancer Res; 2021 Dec; 27(24):6662-6665. PubMed ID: 34580112
[TBL] [Abstract][Full Text] [Related]
20. Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?
Gatto L; Franceschi E; Tosoni A; Nunno VD; Bartolini S; Brandes AA
Immunotherapy; 2022 Jul; 14(10):799-813. PubMed ID: 35670093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
